BetaPublic beta

Spending
Lobbying
Coming soon: Congress, Stocks

Spending
- Overview
- Agencies
- Programs
- Recipients
- Awards
Lobbying
Congress
Stocks

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Lobbying
Coming soon: Congress, Stocks

Overview Firms Clients Revolving Door Stands Out

NEUROMOLECULAR PHARMACEUTICALS — Lobbying — Receipts Report

LD-2 disclosure · 1st Quarter - Report (No Activity)

NEUROMOLECULAR PHARMACEUTICALS

via BROWNSTEIN HYATT FARBER SCHRECK, LLP

1st Quarter (Jan 1 - Mar 31) · 2009Posted Apr 9, 2009Filing document ↗LDA record ↗

Income$20Kfee reported

Client

Name: NEUROMOLECULAR PHARMACEUTICALS
Description: Pharmaceutical company
Location: * Undetermined

Registrant

Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Description: Law firm
Location: Washington, District of Columbia, United States of America

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.